Aug 06, 2024 4:05 pm EDT Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024
May 29, 2024 4:01 pm EDT Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
Feb 12, 2024 7:00 am EST Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
Dec 20, 2023 4:30 pm EST Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Nov 28, 2023 7:00 am EST Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
Nov 09, 2023 7:00 am EST Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
Oct 02, 2023 4:52 pm EDT Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares